Matinas BioPharma Holdings, Inc. (MTNB) Earnings History
Annual and quarterly earnings data from 2012 to 2024
Loading earnings history...
MTNB EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
MTNB Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | - | - | - |
| 2023 | 100.0% | -2168.4% | -2093.2% |
| 2022 | -423.1% | -771.3% | -658.6% |
| 2021 | -44090.9% | -74954.5% | -70554.5% |
| 2020 | -8968.8% | -15288.4% | -14177.0% |
Download Data
Export MTNB earnings history in CSV or JSON format
Free sign-in required to download data
Matinas BioPharma Holdings, Inc. (MTNB) Earnings Overview
As of May 8, 2026, Matinas BioPharma Holdings, Inc. (MTNB) reported trailing twelve-month net income of -$17M, reflecting +5.7% year-over-year growth. The company earned $-3.22 per diluted share over the past four quarters.
Looking at the long-term picture, MTNB's historical earnings data spans multiple years. The company achieved its highest annual net income of -$116,075 in fiscal 2012.
Matinas BioPharma Holdings, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ARQT (-$2M net income, -4.3% margin), NKTR (-$164M net income, -297.1% margin), PRAX (-$327M net income), MTNB has comparable earnings metrics. Compare MTNB vs ARQT →
MTNB Earnings vs Peers
Earnings metrics vs comparable public companies
MTNB Historical Earnings Data (2012–2024)
13 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$24M | -5.7% | -$25M | $-4.98 | - | - |
| 2023 | -$23M | -9.3% | -$24M | $-5.28 | -2093.2% | -2168.4% |
| 2022 | -$21M | +9.8% | -$25M | $-3.00 | -658.6% | -771.3% |
| 2021 | -$23M | -3.7% | -$25M | $-5.04 | -70554.5% | -74954.5% |
| 2020 | -$22M | -29.2% | -$24M | $-5.23 | -14177.0% | -15288.4% |
| 2019 | -$17M | -23.4% | -$19M | $-5.37 | -19343.4% | -21067.4% |
| 2018 | -$14M | +9.1% | -$15M | $-7.18 | -11760.4% | -12230.9% |
| 2017 | -$15M | -103.8% | -$17M | $-8.56 | -10345.9% | -11024.6% |
| 2016 | -$8M | +16.8% | -$8M | $-6.59 | - | - |
| 2015 | -$9M | +10.6% | -$10M | $-8.87 | -4697.0% | -5096.0% |
See MTNB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MTNB Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MTNB vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonMTNB — Frequently Asked Questions
Quick answers to the most common questions about buying MTNB stock.
Is MTNB growing earnings?
MTNB EPS stands at $-3.22, with +5.7% growth matching the 5-year CAGR of N/A. TTM net income is $-17M. Earnings trajectory remains consistent.
What are MTNB's profit margins?
Matinas BioPharma Holdings, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are MTNB's earnings?
MTNB earnings data spans 2012-2024. The current earnings trend is +5.7% YoY. Historical data enables comparison across business cycles.